Evaluation of miR-122 level in the plasma of chronically HCV infected patients
- Authors: Gholami M.1, Ravanshad M.1, Alavian S.2, Baesi K.3, Moallemi S.3
-
Affiliations:
- Department of Medical Virology
- Founder of Iran Hepatitis Network & Tehran Hepatitis Center
- Department of Medical Virology, Iranian Research Center for HIV AIDS (IRCHA) Iranian Institute for Reduction of High-Risk Behaviors
- Issue: Vol 50, No 2 (2016)
- Pages: 242-245
- Section: Molecular Cell Biology
- URL: https://journal-vniispk.ru/0026-8933/article/view/162582
- DOI: https://doi.org/10.1134/S0026893316020072
- ID: 162582
Cite item
Abstract
MicroRNAs (miRNAs) are small non-coding RNA molecules, which have an important function in regulating RNA stability and gene expression. They also can circulate in a cell-free form in the blood thatmakes them potential disease markers. The liver contains various classes of miRNAs in which miR-122 accounts for about 70% of all miRNAs and it has been proved that its level increases in case of liver damage. Here, we investigated plasma levels of miR-122 as a useful disease parameter in patients with chronic hepatitis C (CHC) infection. Thirty five hemophilia and thalassemia patients with CHC were studied. The total RNA was extracted from plasma samples, and miR-122 levels were measured by qPCR and then compared with the specific liver markers. The plasma levels of alanine transaminase (ALT) and aspartate transaminase(AST) were correlated with plasma miR-122 level in CHC patients, and the level of circulating miR-122 in healthy individual groups were rarely lower than those of patients with CHC. In our study, miR-122 levels correlated well with markers of liver inflammatory activity. Plasma miR-122 can be assumed to be another marker in liver similar to the currently used specific markers such as ALT and AST for evaluation of liver damage in hepatitis C virus (HCV) infected patients. Moreover, the correlation between miR-122 and ALT was shown to be higher than between miR-122 and AST.
Keywords
About the authors
M. Gholami
Department of Medical Virology
Email: Ravanshad@modares.ac.ir
Iran, Islamic Republic of, Tehran, 14115-111
M. Ravanshad
Department of Medical Virology
Author for correspondence.
Email: Ravanshad@modares.ac.ir
Iran, Islamic Republic of, Tehran, 14115-111
S.-M. Alavian
Founder of Iran Hepatitis Network & Tehran Hepatitis Center
Email: Ravanshad@modares.ac.ir
Iran, Islamic Republic of, Tehran, 19945-581
K. Baesi
Department of Medical Virology, Iranian Research Center for HIV AIDS (IRCHA) Iranian Institute for Reduction of High-Risk Behaviors
Email: Ravanshad@modares.ac.ir
Iran, Islamic Republic of, Tehran, 14197-313
S. Moallemi
Department of Medical Virology, Iranian Research Center for HIV AIDS (IRCHA) Iranian Institute for Reduction of High-Risk Behaviors
Email: Ravanshad@modares.ac.ir
Iran, Islamic Republic of, Tehran, 14197-313
Supplementary files
